Halozyme Therapeutics | HALO - Cost Of Sales


Halozyme Therapeutics reported $108.68M in Cost of Sales for its fiscal quarter ending in June of 2026.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 28.32M 3.52M Jun/2026
Agios Pharmaceuticals USD 1.32M 560K Mar/2026
Alnylam Pharmaceuticals USD 298.45M 87.33M Jun/2026
Amarin USD 26.05M 1.41M Dec/2025
Amgen USD 1.87B 271M Jun/2026
Baxter International USD 1.93B 118M Jun/2026
Cara Therapeutics USD 0 0 Mar/2025
Cytokinetics USD 5.59M 5.43M Jun/2026
Eli Lilly USD 3.27B 309M Jun/2026
Halozyme Therapeutics USD 108.68M 67K Jun/2026
Intrexon USD 1.01M 344K Jun/2024
Ionis Pharmaceuticals USD 2.74M 261K Jun/2026
MannKind USD 34.21M 5.38M Jun/2026
Minerva Neurosciences 386K 31K Jun/2024
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Pfizer USD 4.09B 498M Jun/2026
Rigel Pharmaceuticals USD 8.03M 5.22M Sep/2024
United Therapeutics USD 99.5M 33.9M Jun/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024